Table 4. Significantly opposing inflammatory gene variants associated with progression in NMIBC patients in the discovery cohort who received BCG and TUR only treatment.
| SNP | Gene | MAF | MOI | TUR only | BCG | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| # of events | # of no events | HR (95% CI)* | P-value | # of events | # of no events | HR (95% CI)* | P-value | ||||
| rs1800686# | CD40 | 0.24 | REC | 9\10\0 | 74\46\5 | NA | NA | 24\26\7 | 83\59\6 | 3.81 (1.55-9.37 | <0.01 |
| rs2071081 | CD4 | 0.21 | REC | 10\9\0 | 81\39\5 | NA | NA | 33\15\9 | 93\49\6 | 3.19 (1.36-7.47) | 0.01 |
| rs7089861 | IL2RA | 0.28 | REC | 13\6\0 | 66\50\9 | NA | NA | 28\21\8 | 76\60\11 | 3.16 (1.38-7.22) | 0.01 |
| rs1210225 | CD34 | 0.21 | DOM | 12\7\0 | 74\47\4 | 0.92 (0.29-2.94) | 0.89 | 34\21\2 | 96\46\6 | 2.11 (1.16-3.83) | 0.01 |
| rs709592# | CSF3 | 0.37 | REC | 10\5\4 | 50\59\16 | 0.91 (0.18-4.70) | 0.91 | 21\21\15 | 61\69\16 | 2.24 (1.14-4.40) | 0.02 |
| rs752118# | CD40 | 0.26 | REC | 9\10\0 | 73\47\5 | NA | NA | 24\25\8 | 83\59\6 | 2.88 (1.22-6.80) | 0.02 |
| rs12309# | CSF3 | 0.41 | DOM | 6\11\2 | 40\64\21 | 1.13 (0.35-3.67) | 0.83 | 31\13\13 | 48\74\26 | 0.52 (0.29-0.93) | 0.03 |
| rs2302777 | CSF3 | 0.41 | DOM | 6\11\2 | 39\65\21 | 1.11 (0.34-3.60) | 0.86 | 31\13\13 | 48\75\25 | 0.52 (0.29-0.93) | 0.03 |
| rs2227315# | CSF3 | 0.36 | REC | 10\5\4 | 50\58\15 | 0.92 (0.18-4.74) | 0.92 | 21\20\14 | 60\66\16 | 2.15 (1.07-4.32) | 0.03 |
| rs12722588# | IL2RA | 0.17 | DOM | 15\4\0 | 83\40\2 | 0.95 (0.29-3.07) | 0.93 | 37\18\2 | 103\43\2 | 1.92 (1.04-3.57) | 0.04 |
| rs2302776# | CSF3 | 0.49 | DOM | 2\13\4 | 33\58\34 | 1.84 (0.39-8.64) | 0.44 | 26\18\13 | 39\69\40 | 0.55 (0.31-0.98) | 0.04 |
| rs709591# | CSF3 | 0.37 | REC | 10\5\4 | 50\59\16 | 0.91 (0.18-4.70) | 0.91 | 21\21\15 | 61\69\17 | 2.05 (1.05-4.00) | 0.04 |
| rs7093069# | IL2RA | 0.17 | DOM | 15\4\0 | 83\40\2 | 0.95 (0.29-3.07) | 0.93 | 37\18\2 | 103\43\2 | 1.92 (1.04-3.57) | 0.04 |
| rs4794823# | CSF3 | 0.37 | REC | 10\5\4 | 51\57\16 | 0.93 (0.18-4.80) | 0.93 | 21\21\15 | 61\70\17 | 1.96 (1.00-3.84) | 0.05 |
| rs4795418# | CSF3 | 0.37 | REC | 10\5\4 | 51\58\16 | 0.91 (0.18-4.70) | 0.91 | 21\21\15 | 61\70\17 | 1.96 (1.00-3.84) | 0.05 |
*Adjusted by age, gender, smoking status, carcinoma in situ, tumor size, tumor grade, and treatment.
#SNPs with high linkage disequilibrium (LD; r2>0.8): rs1800686 and rs752118 in LD; rs12309 and rs2302777 in LD; rs709592 and rs709591 in LD; rs709592 and rs4795418 in LD; rs709592 and rs2227315 in LD; rs709592 and rs4794823 in LD; rs709591 and rs4795418 in LD rs709591 and rs2227315 in LD; rs709591 and rs4794823 in LD; rs4795418 and rs2227315 in LD; rs4795418 and rs4794823 in LD; rs2227315 and rs4798423 in LD; rs12722588 and rs7093069 in LD.
TUR: transurethral resection; BCG: Bacillus Calmette–Guérin immunotherapy; MAF: minor allele frequency; MOI: model of inheritance; Rec: recessive; dom: dominant; HR: hazard ratio; CI: confidence interval.